Researchers highlighted the complexities of using amyloid immunotherapy for early Alzheimer’s disease, discussing its clinical benefits, challenges, and broader health implications. Despite some positive results, concerns over adverse effects, trial biases, and cost hinder widespread adoption.
Vic Neufeld | Executive Chairman, Havn Life Sciences | Psychedelic Finance
You were on the ground floor of scaling up one of the largest cannabis companies on the planet. What similarities do you see from the